Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467167 | 1.00 | HRH3 (0.55) | HRH3ROCK2CYP4F2CYP4A11ROCK1 | |
| Hydrochloric Acid SCHEMBL29271375 | 0.98 | HRH3 (0.54) | HRH3ROCK2CYP4F2CYP4A11ROCK1 | |
| Hydrochloric Acid SCHEMBL30986706 | 0.98 | HRH3 (0.54) | HRH3ROCK2CYP4F2CYP4A11ROCK1 | |
| SCHEMBL2153847 | 0.81 | HRH3 (0.59) | HRH3MPOCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22968978 | 0.80 | HRH3 (0.50) | HRH3ROCK2CYP4F2CYP4A11ROCK1 | |
| SCHEMBL4196662 | 0.76 | HRH3 (0.54) | HRH3MPOCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22968793 | 0.76 | ROCK2 (0.45) | ROCK2MPOIDO1DAO | |
| SCHEMBL22968985 | 0.76 | PDE4B (0.52) | ROCK2IDO1DAO | |
| SCHEMBL22968941 | 0.76 | PDE4B (0.52) | ROCK2ROCK1IDO1DAO | |
| SCHEMBL171388 | 0.74 | HRH3 (0.57) | HRH3CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206861-A | Fused heteroaryl compounds useful as RIPK1 inhibitors | 比西切姆有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021029632-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-18 | — | — | WO | disclosed |
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | HRH3 3096/4885ROCK2 350/4885CYP4F2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.